Laboratory methods for KRASmutation analysis

Expert Review of Molecular Diagnostics

Volumn 11, Issue 6, 2011, Pages 635-642

  Anderson, Steven M ^a  

^a LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

cetuximab; colorectal cancer; KRAS gene; mutation analysis; panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER TISSUE; COLON CANCER; COLORECTAL CANCER; DNA HYBRIDIZATION; DRUG RESPONSE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INTRACELLULAR SIGNALING; LIMIT OF DETECTION; LUNG CANCER; MOLECULAR PROBE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; LUNG NON SMALL CELL CANCER; METABOLISM; METHODOLOGY; MOLECULAR DIAGNOSIS; NUCLEOTIDE SEQUENCE; TRANSITION TEMPERATURE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSITION TEMPERATURE;

EID: 79960238239     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.42     Document Type: Review

References (45)

1. Wang HL, Lopategui J, Amin MB et al. KRAS mutation testing in human cancers: the pathologists role in the era of personalized medicine. Adv. Anat. Pathol. 17, 23-32 (2010)
2. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thoracic Soc. 6, 201-205 (2008)
3. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J. Mol. Diagn. 10, 493-495 (2008)
4. American Cancer Society. 2010 Cancer Facts and Figures. ACS, GA, USA (2010)
5. Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer-an update of recent developments. Head Neck Oncol. 2, 8-13 (2010)
6. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008) (Pubitemid 351171687)
7. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab and advanced colon cancer. N. Engl. J. Med. 359, 1757-1765 (2008)
8. Van Custem E, Lang I, D'Haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol. 26, 5S (2008)
9. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab. J. Clin. Oncol. 26, 178S (2008)
10. De Roock W, Piessevaux H, De Shutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508-515 (2008) (Pubitemid 351325672)
11. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007) (Pubitemid 47325606)
12. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96, 1166-1169 (2007) (Pubitemid 46625066)
13. Amado RG, Wolf M, Peters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colon cancer. J. Clin. Oncol. 26, 1626-1634 (2008)
14. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colon cancer. J. Clin. Oncol. 26, 5705-5712 (2008)
15. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2095 (2009)
16. National Comprehensive Cancer Network Guidelines on Colon and Rectal Cancers. NCCN, PA, USA (2008).
17. Miller VA, Riely GJ, Zakowski MF et al. Molecular characterization of bronchioloavlveolar carcinoma and adenocarcinoma, brochioloavelolar carcinoma subtype, predict response to erolotinib. J. Clin. Oncol. 26, 1472-1478 (2008)
18. Hirsch FR, Varella-Garcia M, Bunn PA et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034-5042 (2006) (Pubitemid 46631407)
19. Han SW, Kim TY, Leon YK et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. 12, 2538-2544 (2006)
20. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 13, 2890-2896 (2007) (Pubitemid 46849563)
21. Jimeno A, Messersmith WA, Hirsch FR et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 27, 1130-1135 (2009)
22. Van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an european quality assurance program. Virchows Archiv. 453, 417-431 (2008)
23. Neumann J, Zeindl-Eberhart E, Kirchner T et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Prac. 205, 858-862 (2009)
24. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset. Modern Pathol. 22, 508-515 (2009)
25. Clayton SJ, Scott FM, Walker J et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutaion detection using ARMS allele-specific amplification. Clin. Chem. 46, 1929-1938 (2000)
26. Lang AH, Drexel H, Geller-Rhomberg S et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J. Mol. Diagn. 13, 23-28 (2011)
27. Ogino S, Kawasaki T, Brahmandam M et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J. Mol. Diagn. 7, 413-421 (2005) (Pubitemid 41149657)
28. Tsiatis AC, Norris-Kirby A, Rich RG et al. Comparison of sanger sequencing, pyrosequencing, and melt curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J. Mol. Diagn. 12, 425-432 (2010)
29. Pritchard CC, Akagi L, Reddy PL, Joseph L, Tait JF. COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clin. Pathol. 10, 1-10 (2010)
30. TheraScreen® Package Insert, DsX, Manchester, UK (2009)
31. PyroMark® Package Insert, Qiagen, Valencia, CA, USA (2010)
32. Angulo B, Garcia-Garcia E, Martinez R et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J. Mol. Diagn. 12, 292-299 (2010)
33. Whitehall V, Tran K, Umapathy A et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J. Mol. Diagn. 11, 543-552 (2009)
34. Weichart W, Schewe C, Lehmann A et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J. Mol. Diagn. 12, 35-42 (2010)
35. Oliner K, Juan T, Suggs S et al. A comparability study of 5 commercial KRAS tests. Diagn. Pathol. 5, 23-29 (2010)
36. De Roock W, Jonker D, Di Nicolantonio F et al. Association of KRAS G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820 (2010)
37. Baldus SE, Schaefer KL, Engers R et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16, 790-799 (2010)
38. Ogino S, Kawasaki T, Brahmandan M et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J. Mol. Diagn. 4, 413-421 (2005) (Pubitemid 41149657)
39. Samowitz W, Curtin K, Schaffer P et al. Relationship of Ki-ras mutation in colon cancer to tumor location, stage and survivorship: a population based study. Cancer Epidemiol. Biomarkers Prev. 9, 1193-1197 (2000)
40. Cai L, Kam-Morgan L, Kallam E et al. Detection of KRAS oncogene mutations using PCR and pyrosequencing methods. Presented at: ASCO-NCI-EORTC Annual Meeting: Molecular Markers in Cancer. Brussels, Belgium, 14-17 October 2009
41. Faulkner NE, Da Silva MM, Heim RA et al. KRAS mutation analyses of >16,500 colorectal carcinomas. Presented at: ASCO-NCI-EORTC Annual Meeting: Molecular Markers in Cancer. Brussels, Belgium, 18-20 October 2010
42. Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine needle aprirate biopsies. World J. Surg. 34, 2589-2594 (2010)
43. Lapakos O, Gologan O, Liu Y et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod. Pathol. 19, 907-913 (2006)
44. Holdhoff M, Schmidt K, Donehower R et al. Analysis of circulating tumor DNA to confirm somatic mutations. J. Natl Cancer Inst. 101, 1284-1287 (2009)
45. KRAS European quality-assurance program 〈http://kras.equascheme. org〉